Emergent BioSolutions (EBS) Misses Q1 EPS by 65c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.21, $0.65 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $156.1 million versus the consensus estimate of $205 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c
- BeyondSpring Inc. (BYSI) Reports Q2 Loss of $0.02
- Trump: Iran cannot have, in any way, shape, or form, a nuclear weapon
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
